Insmed reported $311.68M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Cytokinetics USD 131.06M 28.66M Jun/2025
DBV Technologies USD 49.42M 9.04M Jun/2025
Dynavax Technologies USD 118.23M 49.85M Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Insmed USD 311.68M 72.45M Jun/2025
Novartis USD 31.71B 3.02B Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025